Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 4, 2009, Pages 290-296

  Barillari, Giovanni ^a   Fabbro, Elisabetta ^b   Pasca, Samantha ^a   Bigotto, Enrico ^a  

^a Center for Hemorrhagic and Thrombotic Disorders   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Cardiovascular risk; Coagulation factors; Metabolic syndrome; Oxidative stress; Thrombosis; Type 2 diabetes mellitus

Indexed keywords

3 NITROTYROSINE; ANTITHROMBIN III; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; ORAL ANTIDIABETIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DIABETIC DIET; FEMALE; HUMAN; HUMAN TISSUE; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOSIS;

ADULT; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE;

EID: 67649512430     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328329e49b     Document Type: Article

References (26)

1. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, prognosis and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ. 2005:1 -11.
2. Jack L, Boseman L, Vinicor F. Aging Americans and diabetes. A public health and clinical response. Geriatric. 2004; 59:14-17.
3. Lovejoy JC. The influence of dietary fat on insulin resistance. Curr Diab Re. 2002; 2:435-440.
4. Hu FB. Sedentary lifestyle and risk of obesity and type 2 diabetes. Lipid. 2003; 38:103-108.
5. Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Throm. 2002; 32:269-273.
6. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemos. 2008; 99:995-1000.
7. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Endocrinol Meta. 2001; 280:E745-E751.
8. Hajer GR, van Haeften TW, Visseren FL Adipose tissue dysfunction in obesity, diabetes and vascular disease. Eur Heart. 2008; 29:2959-2971.
9. Hadi HA, Suwadi JA. Endothelial dysfunction in diabetes mellitus. Vase Health Risk Mana. 2007; 3:853-876.
10. Mäkimattila S, Yki-Järvinen H. Endothelial dysfunction in human diabetes. Curr Diab Re. 2002; 2:26-36.
11. Mäkimattila S, Liu ML, Vakkilainen J, Schlenzka A, Lahndenperä S, Syvanne M, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, ooxided LDL and antioxidants. Diabetes Car. 1999; 22:973-981.
12. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologi. 2001; 44:834-8380.
13. Kanaya AM, Wassel Fyr C, Vittinghoff E, Harris TB, Park SW, Goodpaster BH, et al. Adipocytokines and incident diabetes mellitus in older adults. Arch Intern Me. 2006; 166:350-356.
14. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Me. 2007; 262:157-172.
15. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Me. 2005; 5:323-332.
16. Varol E, Ozaydin L, Sahin M, Altinbas A, Kosar F. vWf levels as a circulating marker of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Indian Heart. 2005; 57:655-657.
17. Meigs JB, O'donnel CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabete. 2006; 55:530-537.
18. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemos. 2005; 3:1879-1883.
19. Erem C, Hacihasanog̃lu A, Celik S, Ovali E, Ersöz HO, Ukiņ K, et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Prat. 2005; 14:22-30.
20. Bulló M, Casas-Agustench P, Amigó-Correig P, Aranceta J, Salas-Salvadó J. Inflammation, obesity and comorbidities: the role of diet. Public Healt. Wufr2007; 10:1164-1172.
21. Fattah MA, Shaheen MH, Mahfouz MH. Disturbances of haemostasis in diabetes mellitus. Dis Marker. 2003-2004; 19:251 -258.
22. Rana JS, Nieuwdorp M, Jukema J W, Kastelein JJ. Cardiovascular metabolic syndrome: an interplay of obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Meta. 2007; 9:218-232.
23. Morrish NJ, Wanq SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologi. 2001; 44 (Suppl 2):S14-S21.
24. Ersov C, Kivici S, Budak F, Oral B, Glucu M, Duran C, et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Prac. 2008; 81:56-60.
25. Baalbaki SA, Bell DS. Insulin resistance and thrombogenesis : recent insights and therapeutic implications. Endocr Prac. 2007; 13:679-686.
26. Dentali F, Romualdi E, Ageno W. The metabolic syndrome and the risk of thrombosis. Haematologic. 2007; 92:297-299.